The ERP Biomarker Qualification Consortium was launched today by pharmaceutical industry members with the goal of qualifying event-related potential (ERP) biomarkers to aid the development of new investigational therapies for people with schizophrenia in accordance with FDA guidelines.
Cadent Therapeutics, a company focused on the development of breakthrough therapies to improve the lives of patients with movement and neurological disorders, today announced that Jodie Morrison has been appointed Chief Executive Officer and has also joined Cadent’s Board of Directors. Ms. Morrison brings to Cadent more than 20 years of executive leadership...
Cadent Therapeutics Secures $40 Million Series B Financing to Advance Pipeline of Novel Therapies for Movement and Cognitive Disorders
Cadent Therapeutics, a company focused on the development of breakthrough therapies to improve the lives of patients with movement and cognitive disorders, today announced that it has raised $40 million in a Series B financing. In addition, the company has appointed Bob (Ibrahim) Dagher, M.D., as Chief Medical Officer.
Cadent Therapeutics, a precision neuroscience company developing novel medicines to restore movement and cognitive function in patients with neurological and psychiatric disease, today announced the initiation of a Phase 1 clinical study for its lead product candidate CAD-1883. The compound is a selective first-in-class positive allosteric modulator of the small conductance calcium-activated potassium (SK) channel.
Precision neuroscience company Cadent Therapeutics has earned a milestone payment from Novartis for the initiation of a Phase1 clinical study of a subtype selective NMDA receptor negative allosteric modulator (NAM) for the treatment of treatment-resistant depression.